ID   MDA-MB-231
AC   CVCL_0062
SY   MDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231; MDA-MB231; MDAMB-231; MDAMB231; MDA-231; MDA231; MB231; MD Anderson-Metastatic Breast-231
DR   BTO; BTO:0000815
DR   CLO; CLO_0007634
DR   CLO; CLO_0037291
DR   EFO; EFO_0001209
DR   MCCL; MCC:0000313
DR   CLDB; cl3402
DR   CLDB; cl3404
DR   CLDB; cl3405
DR   CLDB; cl4945
DR   AddexBio; C0006002/58
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-TABM-157
DR   ArrayExpress; E-TABM-244
DR   ATCC; CRL-12532
DR   ATCC; HTB-26
DR   ATCC; CRM-HTB-26
DR   BCRC; 60425
DR   BCRJ; 0164
DR   BioSample; SAMN03472205
DR   BioSample; SAMN05292460
DR   BioSample; SAMN07710033
DR   BioSample; SAMN07710034
DR   BioSample; SAMN07710035
DR   BioSample; SAMN07710036
DR   BioSample; SAMN07710037
DR   BioSample; SAMN07710038
DR   BioSample; SAMN07710039
DR   BioSample; SAMN10987764
DR   CCLE; MDAMB231_BREAST
DR   CCRID; 3111C0001CCC000014
DR   CCRID; 3131C0001000700104
DR   CCRID; 3142C0001000000323
DR   CCRID; 3153C0001000000222
DR   CCTCC; GDC0297
DR   Cell_Model_Passport; SIDM00146
DR   ChEMBL-Cells; CHEMBL3307960
DR   ChEMBL-Targets; CHEMBL400
DR   CLS; 300275/NA
DR   Cosmic; 687494
DR   Cosmic; 871146
DR   Cosmic; 875878
DR   Cosmic; 877450
DR   Cosmic; 894087
DR   Cosmic; 897423
DR   Cosmic; 904377
DR   Cosmic; 905960
DR   Cosmic; 934536
DR   Cosmic; 944294
DR   Cosmic; 974235
DR   Cosmic; 991324
DR   Cosmic; 997929
DR   Cosmic; 1010924
DR   Cosmic; 1018477
DR   Cosmic; 1027053
DR   Cosmic; 1044226
DR   Cosmic; 1046950
DR   Cosmic; 1047693
DR   Cosmic; 1071900
DR   Cosmic; 1092613
DR   Cosmic; 1136369
DR   Cosmic; 1152528
DR   Cosmic; 1175833
DR   Cosmic; 1176602
DR   Cosmic; 1176636
DR   Cosmic; 1183773
DR   Cosmic; 1219444
DR   Cosmic; 1287926
DR   Cosmic; 1289395
DR   Cosmic; 1305383
DR   Cosmic; 1309003
DR   Cosmic; 1312370
DR   Cosmic; 1434952
DR   Cosmic; 1436032
DR   Cosmic; 1466805
DR   Cosmic; 1477428
DR   Cosmic; 1481426
DR   Cosmic; 1524347
DR   Cosmic; 1571793
DR   Cosmic; 1609458
DR   Cosmic; 1927242
DR   Cosmic; 1945862
DR   Cosmic; 1998455
DR   Cosmic; 2009512
DR   Cosmic; 2036667
DR   Cosmic; 2164997
DR   Cosmic; 2301528
DR   Cosmic; 2318377
DR   Cosmic; 2361355
DR   Cosmic; 2560256
DR   Cosmic-CLP; 905960
DR   DepMap; ACH-000768
DR   DSMZ; ACC-732
DR   ECACC; 92020424
DR   FCS-free; 253-2-521-2-3-3
DR   GDSC; 905960
DR   GEO; GSM812
DR   GEO; GSM2124
DR   GEO; GSM49953
DR   GEO; GSM49954
DR   GEO; GSM50184
DR   GEO; GSM50248
DR   GEO; GSM69194
DR   GEO; GSM155213
DR   GEO; GSM185093
DR   GEO; GSM185094
DR   GEO; GSM274653
DR   GEO; GSM344349
DR   GEO; GSM344399
DR   GEO; GSM350547
DR   GEO; GSM378148
DR   GEO; GSM388213
DR   GEO; GSM421873
DR   GEO; GSM459713
DR   GEO; GSM481304
DR   GEO; GSM587393
DR   GEO; GSM587394
DR   GEO; GSM750781
DR   GEO; GSM799321
DR   GEO; GSM799384
DR   GEO; GSM820814
DR   GEO; GSM820815
DR   GEO; GSM820816
DR   GEO; GSM839034
DR   GEO; GSM847036
DR   GEO; GSM847401
DR   GEO; GSM844594
DR   GEO; GSM844595
DR   GEO; GSM887295
DR   GEO; GSM888370
DR   GEO; GSM967818
DR   GEO; GSM1008905
DR   GEO; GSM1053716
DR   GEO; GSM1153390
DR   GEO; GSM1172979
DR   GEO; GSM1172889
DR   GEO; GSM1181242
DR   GEO; GSM1181365
DR   GEO; GSM1214569
DR   GEO; GSM1238120
DR   GEO; GSM1374651
DR   GEO; GSM1374652
DR   GEO; GSM1401658
DR   GEO; GSM1613823
DR   GEO; GSM1670080
DR   GEO; GSM1833624
DR   GEO; GSM2095710
DR   GEO; GSM2095711
DR   GEO; GSM2124643
DR   IARC_TP53; 6
DR   IBRC; C10684
DR   ICLC; HTL99004
DR   IZSLER; BS TCL 223
DR   KCB; KCB 200776YJ
DR   KCLB; 30026
DR   LiGeA; CCLE_752
DR   LINCS_HMS; 50058
DR   LINCS_LDP; LCL-1461
DR   Lonza; 815
DR   MetaboLights; MTBLS337
DR   MetaboLights; MTBLS387
DR   MetaboLights; MTBLS678
DR   NCBI_Iran; C578
DR   NCI-DTP; MDA-MB-231
DR   PharmacoDB; MDAMB231_900_2019
DR   PRIDE; PXD000239
DR   PRIDE; PXD000397
DR   PRIDE; PXD000691
DR   PRIDE; PXD000914
DR   PRIDE; PXD001553
DR   PRIDE; PXD002192
DR   PRIDE; PXD002649
DR   PRIDE; PXD005292
DR   PRIDE; PXD005942
DR   PRIDE; PXD010634
DR   SKY/M-FISH/CGH; 2815
DR   TOKU-E; 2394
DR   Wikidata; Q17577870
RX   CelloPub=CLPUB00423;
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   DOI=10.4172/2157-7145.S2-005;
RX   PubMed=730202;
RX   PubMed=833871;
RX   PubMed=1000504;
RX   PubMed=1000505;
RX   PubMed=1000506;
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=4412247;
RX   PubMed=6582512;
RX   PubMed=6935474;
RX   PubMed=7000337;
RX   PubMed=7272986;
RX   PubMed=7459858;
RX   PubMed=7902062;
RX   PubMed=8824553;
RX   PubMed=9671407;
RX   PubMed=10700174;
RX   PubMed=11687795;
RX   PubMed=11697798;
RX   PubMed=12068308;
RX   PubMed=12353263;
RX   PubMed=12661003;
RX   PubMed=12800145;
RX   PubMed=15677628;
RX   PubMed=15748285;
RX   PubMed=15767549;
RX   PubMed=15900046;
RX   PubMed=16049480;
RX   PubMed=16142302;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=17088437;
RX   PubMed=17157791;
RX   PubMed=18277095;
RX   PubMed=18386134;
RX   PubMed=18516279;
RX   PubMed=18714363;
RX   PubMed=19372543;
RX   PubMed=19582160;
RX   PubMed=19593635;
RX   PubMed=20070913;
RX   PubMed=20164919;
RX   PubMed=21378333;
RX   PubMed=21778573;
RX   PubMed=22068913;
RX   PubMed=22336246;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=22628656;
RX   PubMed=23151021;
RX   PubMed=23601657;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24009699;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=26055192;
RX   PubMed=26218769;
RX   PubMed=26649326;
RX   PubMed=27331101;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=28287265;
RX   PubMed=28889351;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31092827;
RX   PubMed=31978347;
WW   https://de.wikipedia.org/wiki/MDA-MB-231_(Zelllinie)
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://physics.cancer.gov/docs/bioresource/breast/NCI-PBCF-HTB26_MDA-MB-231_SOP-508.pdf
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=2
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-231
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/MDA-MB-231_Struhl_protocol.pdf
WW   http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-394.html
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   http://tcpaportal.org/mclp/
WW   https://www.phe-culturecollections.org.uk/media/133182/mda-mb-231-cell-line-profile.pdf
WW   https://www.nikonsmallworld.com/galleries/2018-small-world-in-motion-competition/labeling-of-the-microtubule-cytoskeleton-in-a-human-cell-line
WW   https://www.quora.com/What-does-231-stand-for-in-the-MDA-MB-231-cell-line
WW   http://www.cellresource.cn/fdetail.aspx?id=14
WW   http://www.cellresource.cn/fdetail.aspx?id=672
WW   http://www.cellresource.cn/fdetail.aspx?id=1974
WW   http://www.cellresource.cn/fdetail.aspx?id=2173
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: JFCR45 cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Registration: Chiron Master Culture Collection; CMCC 10583 (CMCC #10583).
CC   Doubling time: 1.3 days (PubMed=9671407); 41.9 hours (NCI-DTP); 38 hours (ATCC); ~25-30 hours (DSMZ); ~38 hours (PBCF); 31.43 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   HLA typing: A*02:01,02:17; B*40:02,41:01; C*02:02:02,17; DPB1*02:01:02,17:01; DQB1*02:02,03:01:01; DRB1*07:01,13:05 (PubMed=15748285).
CC   HLA typing: A*02:17,02:01; B*41:01,40:02; C*17:01,02:02; DQA1*02:01,02:01; DQB1*03:04,03:04; DRB1*13:05,07:01 (PubMed=25960936).
CC   Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger).
CC   Sequence variation: Heterozygous for BRAF p.Gly464Val (c.1391G>T) (ClinVar=VCV000040364) (PubMed=17088437; PubMed=19593635; ATCC).
CC   Sequence variation: Homozygous for CDKN2A deletion (PubMed=19593635; ATCC).
CC   Sequence variation: Heterozygous for KRAS p.Gly13Asp (c.38G>A) (ClinVar=VCV000012580) (PubMed=12068308; PubMed=17088437; PubMed=19593635; ATCC).
CC   Sequence variation: TERT c.228C>T (-124C>T); in promoter (PubMed=31068700).
CC   Sequence variation: Homozygous for TP53 p.Arg280Lys (c.839G>A) (ClinVar=VCV000376657) (PubMed=15900046; PubMed=16541312; PubMed=17088437; PubMed=18277095; PubMed=28889351; ATCC).
CC   Omics: Array-based CGH.
CC   Omics: Cell surface proteome.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: Glycoproteome analysis by proteomics.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: N-glycan profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Secretome proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.95%; Native American=0%; East Asian, North=2.44%; East Asian, South=0%; South Asian=7.42%; European, North=28.16%; European, South=60.03% (PubMed=30894373).
CC   Misspelling: MDA-MD-231; In Cosmic 1071900 and Cosmic 1176602.
CC   Misspelling: MDA-321; In GEO GSM459713.
CC   Misspelling: MDA-MG-231; In PubMed=6582512.
CC   Misspelling: MD-MB-231; In PRIDE PXD010634.
CC   Misspelling: MD-MBA-231; Occasionally.
CC   Discontinued: ATCC; CRL-12532; probable.
CC   Discontinued: CLS; 300275; true.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 13
ST   D16S539: 12
ST   D18S51: 11,16
ST   D19S433: 11,14
ST   D21S11: 30,33.2 (CCRID; CLS; PubMed=28889351)
ST   D21S11: 33.2 (DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200)
ST   D2S1338: 20,21
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8,9
ST   D8S1179: 13
ST   FGA: 22,23
ST   Penta D: 11,14
ST   Penta E: 11
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 15,18 (ATCC; CCRID; Cosmic-CLP; DSMZ; ECACC; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351)
ST   vWA: 15,19 (AddexBio; CLS)
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 35
//
RX   CelloPub=CLPUB00423;
RA   Morrison B.J.;
RT   "Breast cancer stem cells: tumourspheres and implications for therapy.";
RL   Thesis PhD (2010), Griffith University, Australia.
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994).
//
RX   DOI=10.4172/2157-7145.S2-005;
RA   Fang R., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P.,
RA   Furtado M.R.;
RT   "STR profiling of human cell lines: challenges and possible solutions
RT   to the growing problem.";
RL   J. Forensic Res. 2 Suppl. 2:5-5(2011).
//
RX   PubMed=730202; DOI=10.1007/BF02616120;
RA   Cailleau R.M., Olive M., Cruciger Q.V.J.;
RT   "Long-term human breast carcinoma cell lines of metastatic origin:
RT   preliminary characterization.";
RL   In Vitro 14:911-915(1978).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1000504;
RA   Lippman M.E., Bolan G., Huff K.;
RT   "The effects of estrogens and antiestrogens on hormone-responsive
RT   human breast cancer in long-term tissue culture.";
RL   Cancer Res. 36:4595-4601(1976).
//
RX   PubMed=1000505;
RA   Lippman M.E., Bolan G., Huff K.;
RT   "The effects of glucocorticoids and progesterone on hormone-responsive
RT   human breast cancer in long-term tissue culture.";
RL   Cancer Res. 36:4602-4609(1976).
//
RX   PubMed=1000506;
RA   Lippman M.E., Bolan G., Huff K.;
RT   "The effects of androgens and antiandrogens on hormone-responsive
RT   human breast cancer in long-term tissue culture.";
RL   Cancer Res. 36:4610-4618(1976).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4412247; DOI=10.1093/jnci/53.3.661;
RA   Cailleau R.M., Young R., Olive M., Reeves W.J. Jr.;
RT   "Breast tumor cell lines from pleural effusions.";
RL   J. Natl. Cancer Inst. 53:661-674(1974).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=7000337;
RA   Brinkley B.R., Beall P.T., Wible L.J., Mace M.L., Turner D.S.,
RA   Cailleau R.M.;
RT   "Variations in cell form and cytoskeleton in human breast carcinoma
RT   cells in vitro.";
RL   Cancer Res. 40:3118-3129(1980).
//
RX   PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1;
RA   Satya-Prakash K.L., Pathak S., Hsu T.C., Olive M., Cailleau R.M.;
RT   "Cytogenetic analysis on eight human breast tumor cell lines: high
RT   frequencies of 1q, 11q and HeLa-like marker chromosomes.";
RL   Cancer Genet. Cytogenet. 3:61-73(1981).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=7902062;
RA   de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T.,
RA   Mannervik B., Bergh J.;
RT   "Characterization of four doxorubicin adapted human breast cancer cell
RT   lines with respect to chemotherapeutic drug sensitivity, drug
RT   resistance associated membrane proteins and glutathione
RT   transferases.";
RL   Anticancer Res. 13:1425-1430(1993).
//
RX   PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#;
RA   Mullen P., Ritchie A., Langdon S.P., Miller W.R.;
RT   "Effect of Matrigel on the tumorigenicity of human breast and ovarian
RT   carcinoma cell lines.";
RL   Int. J. Cancer 67:816-820(1996).
//
RX   PubMed=9671407; DOI=10.1038/sj.onc.1201814;
RA   Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.;
RT   "Lack of relationship between CDK activity and G1 cyclin expression in
RT   breast cancer cells.";
RL   Oncogene 16:2865-2878(1998).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=11687795; DOI=10.1038/ng754;
RA   Snijders A.M., Nowak N., Segraves R., Blackwood S., Brown N.,
RA   Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S.,
RA   Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N.,
RA   Pinkel D., Albertson D.G.;
RT   "Assembly of microarrays for genome-wide measurement of DNA copy
RT   number.";
RL   Nat. Genet. 29:263-264(2001).
//
RX   PubMed=11697798; DOI=10.1359/jbmr.2001.16.11.2027;
RA   Peyruchaud O., Winding B., Pecheur I., Serre C.-M., Delmas P.,
RA   Clezardin P.;
RT   "Early detection of bone metastases in a murine model using
RT   fluorescent human breast cancer cells: application to the use of the
RT   bisphosphonate zoledronic acid in the treatment of osteolytic
RT   lesions.";
RL   J. Bone Miner. Res. 16:2027-2034(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=12353263; DOI=10.1002/gcc.10107;
RA   Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J.,
RA   Mozziconacci M.-J., Conte N., Murati A., Ginestier C.,
RA   Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C.,
RA   Birnbaum D., Chaffanet M.;
RT   "Reciprocal translocations in breast tumor cell lines: cloning of a
RT   t(3;20) that targets the FHIT gene.";
RL   Genes Chromosomes Cancer 35:204-218(2002).
//
RX   PubMed=12661003; DOI=10.1002/gcc.10196;
RA   Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U.,
RA   Santibanez-Koref M.-F., Schlag P.M., Scherneck S.;
RT   "Identification of microsatellite instability and mismatch repair gene
RT   mutations in breast cancer cell lines.";
RL   Genes Chromosomes Cancer 37:29-35(2003).
//
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11-11(2005).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y.,
RA   Yamazaki K., Hamada J., Tada M., Moriuchi T., Ishikawa Y., Kato Y.,
RA   Tomoda H., Yamori T., Tsuruo T.;
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
//
RX   PubMed=16049480; DOI=10.1038/nature03799;
RA   Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D.,
RA   Viale A.J., Olshen A.B., Gerald W.L., Massague J.;
RT   "Genes that mediate breast cancer metastasis to lung.";
RL   Nature 436:518-524(2005).
//
RX   PubMed=16142302; DOI=10.3892/ijo.27.4.881;
RA   de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D.,
RA   Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G.,
RA   Remacle J.;
RT   "Molecular characterization of breast cancer cell lines by a
RT   low-density microarray.";
RL   Int. J. Oncol. 27:881-892(2005).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W.,
RA   Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=18277095; DOI=10.4161/cbt.7.5.5712;
RA   Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.;
RT   "Analysis of p53 mutation status in human cancer cell lines: a
RT   paradigm for cell line cross-contamination.";
RL   Cancer Biol. Ther. 7:699-708(2008).
//
RX   PubMed=18386134; DOI=10.1007/s10585-008-9169-z;
RA   Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.;
RT   "Characterisation of breast cancer cell lines and establishment of a
RT   novel isogenic subclone to study migration, invasion and
RT   tumourigenicity.";
RL   Clin. Exp. Metastasis 25:549-557(2008).
//
RX   PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004;
RA   Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R.,
RA   Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "The morphologies of breast cancer cell lines in three-dimensional
RT   assays correlate with their profiles of gene expression.";
RL   Mol. Oncol. 1:84-96(2007).
//
RX   PubMed=18714363; DOI=10.1593/neo.08570;
RA   Kischel P., Guillonneau F., Dumont B., Bellahcene A., Stresing V.,
RA   Clezardin P., De Pauw E.A., Castronovo V.;
RT   "Cell membrane proteomic analysis identifies proteins differentially
RT   expressed in osteotropic human breast cancer cells.";
RL   Neoplasia 10:1014-1020(2008).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H., Jochemsen A.G., den Bakker M.A.,
RA   Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=20070913; DOI=10.1186/1471-2407-10-15;
RA   Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M.,
RA   Yamamoto S., Oka M., Hirano T., Sasaki K.;
RT   "Breast cancer cell lines carry cell line-specific genomic alterations
RT   that are distinct from aberrations in breast cancer tissues:
RT   comparison of the CGH profiles between cancer cell lines and primary
RT   cancer tissues.";
RL   BMC Cancer 10:15-15(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21378333;
RA   Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.;
RT   "Reassessment of estrogen receptor expression in human breast cancer
RT   cell lines.";
RL   Anticancer Res. 31:521-527(2011).
//
RX   PubMed=21778573; DOI=10.3233/BD-2010-0307;
RA   Chavez K.J., Garimella S.V., Lipkowitz S.;
RT   "Triple negative breast cancer cell lines: one tool in the search for
RT   better treatment of triple negative breast cancer.";
RL   Breast Dis. 32:35-48(2010).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez F., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23151021; DOI=10.1186/1471-2164-13-619;
RA   Grigoriadis A., Mackay A., Noel E., Wu P.J., Natrajan R., Frankum J.,
RA   Reis-Filho J.S., Tutt A.;
RT   "Molecular characterisation of cell line models for triple-negative
RT   breast cancers.";
RL   BMC Genomics 13:619-619(2012).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33-R33(2013).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L.,
RA   Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M.,
RA   Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24009699; DOI=10.1371/journal.pone.0072704;
RA   Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P.,
RA   Shi S.-L., Chen C.-Y., Li Y.;
RT   "Cell surface-specific N-glycan profiling in breast cancer.";
RL   PLoS ONE 8:E72704-E72704(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X., Bixby L.,
RA   Harrell J.C., Roman E., Adamo B., Troester M., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J.,
RA   Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20-20(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:E954893-E954893(2014).
//
RX   PubMed=26055192; DOI=10.1021/acs.jproteome.5b00375;
RA   Cifani P., Kirik U., Waldemarson S., James P.;
RT   "Molecular portrait of breast-cancer-derived cell lines reveals poor
RT   similarity with tumors.";
RL   J. Proteome Res. 14:2819-2827(2015).
//
RX   PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021;
RA   Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E.,
RA   Kammerer B.;
RT   "Metabolic profiling of breast cancer: differences in central
RT   metabolism between subtypes of breast cancer cell lines.";
RL   J. Chromatogr. B 1000:95-104(2015).
//
RX   PubMed=26649326; DOI=10.1016/j.dib.2015.09.039;
RA   Cox T.R., Schoof E.M., Gartland A., Erler J.T., Linding R.;
RT   "Dataset for the proteomic inventory and quantitative analysis of the
RT   breast cancer hypoxic secretome associated with osteotropism.";
RL   Data Brief 5:621-625(2015).
//
RX   PubMed=27331101; DOI=10.1016/j.dib.2016.05.040;
RA   Aumsuwan P., Khan S.I., Khan I.A., Walker L.A., Dasmahapatra A.K.;
RT   "Gene expression profiling and pathway analysis data in MCF-7 and
RT   MDA-MB-231 human breast cancer cell lines treated with dioscin.";
RL   Data Brief 8:272-279(2016).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20-20(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470;
RA   Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.;
RT   "Glycoproteins in claudin-low breast cancer cell lines have a unique
RT   expression profile.";
RL   J. Proteome Res. 16:1391-1400(2017).
//
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31092827; DOI=10.1038/s41467-019-10148-6;
RA   Liu K., Newbury P.A., Glicksberg B.S., Zeng W.Z.-D., Paithankar S.,
RA   Andrechek E.R., Chen B.;
RT   "Evaluating cell lines as models for metastatic breast cancer through
RT   integrative analysis of genomic data.";
RL   Nat. Commun. 10:2138-2138(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//